Cognition Therapeutics Inc.
This article was originally published in Start Up
Using proprietary assays, Cognition Therapeutics Inc. has discovered small-molecule, highly brain-penetrable drugs that block soluble toxic amyloid beta oligomers in their reactive form, rather than target amyloid beta plaque or expression of the monomer building blocks.
You may also be interested in...
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
AlzProtect SAS believes that Alzheimer's disease is caused by the loss of neuroprotective factors including APP intracellular domain and sAPP alpha, both of which are produced during the metabolism of amyloid precursor protein. The start-up is developing compounds that can stimulate the APP, increasing the production of neuroprotective compounds.
Axerion Therapeutics Inc.
Axerion Therapeutics Inc.'s technology aims to block the binding of Amyloid beta to the prion protein PrP-C, a mechanism its scientists say is the toxic trigger behind neuronal death in Alzheimer's disease. Based at Yale University in New Haven, the team found that mice with AB plaques but no PrP-C showed no cognitive impairment. (Also see "Axerion Therapeutics Inc." - Scrip, 1 Jul, 2010.)